Core Viewpoint - The China Securities Index for Healthcare Equipment and Services has shown a recent increase, but it has experienced declines over the past month, three months, and year-to-date [1]. Group 1: Index Performance - The CSI Healthcare Equipment and Services Index rose by 1.17% to 13,221.28 points with a trading volume of 10.971 billion [1]. - Over the past month, the index has decreased by 9.68%, by 0.46% over the last three months, and by 4.54% year-to-date [1]. Group 2: Index Composition - The index is composed of listed companies in the healthcare sector, reflecting the overall performance of these securities [1]. - The top ten weighted companies in the index include Mindray Medical (9.26%), Aier Eye Hospital (8.31%), and United Imaging Healthcare (7.36%) [1]. - The index's holdings are primarily from the Shenzhen Stock Exchange (60.12%) and the Shanghai Stock Exchange (39.88%) [1]. Group 3: Fund Tracking - Public funds tracking the healthcare index include several funds such as Southern CSI Healthcare Equipment and Services Link A, Tianhong CSI Healthcare Equipment and Services ETF, and others [2].

金融界2025年4月21日消息，中欧医疗健康混合A(003095) 最新净值1.5603元，增长1.85%。该基金近1个 月收益率-1.41%，同类排名1379|4672；近3个月收益率2.56%，同类排名1469|4599；今年来收益 率-0.54%，同类排名2715|4590。 公开资料显示，中欧医疗健康混合A基金成立于2016年9月29日，截至2024年12月31日，中欧医疗健康 混合A规模159.10亿元，基金经理为葛兰。 简历显示：葛兰女士:中国籍。美国西北大学生物医学工程专业博士。历任国金证券股份有限公司研究 所研究员,民生加银基金管理有限公司研究员。2014年10月加入中欧基金管理有限公司,曾任研究员、中 欧明睿新起点灵活配置混合型证券投资基金基金经理(2015年1月29日起至2016年4月22日)、中欧瑾泉灵 活配置混合型证券投资基金基金经理(2015年3月16日起至2016年4月22日)、中欧瑾源灵活配置混合型证 券投资基金基金经理(2015年3月31日起至2016年4月22日)、中欧瑾和灵活配置混合型证券投资基金基金 经理(2015年4月13日起至2016年4月22日)。现任中欧医疗健康混 ...

Group 1 - As of April 18, the total market financing balance is 1.79 trillion yuan, a decrease of 6.28 billion yuan from the previous trading day, marking three consecutive days of decline [1] - The financing balance for the Shanghai Stock Exchange is 913.65 billion yuan, down by 3.34 billion yuan; for the Shenzhen Stock Exchange, it is 873.79 billion yuan, down by 2.93 billion yuan; and for the Beijing Stock Exchange, it is 5.28 billion yuan, down by 19.61 million yuan [1] - On April 18, a total of 1,349 stocks received net financing purchases, with 158 stocks having net purchases exceeding 10 million yuan, and 10 stocks with net purchases over 50 million yuan [1] Group 2 - The top net financing purchase on April 18 was for Tuowei Information, with a net purchase amount of 168 million yuan, followed by Hanwujing and Wo Ai Wo Jia with net purchases of 156 million yuan and 76.97 million yuan, respectively [1] - In terms of industry, the stocks with net purchases exceeding 50 million yuan are concentrated in the computer, pharmaceutical, and non-ferrous metal sectors, with two stocks from each industry on the list [1] - Among the stocks with significant net purchases, 8 are from the main board, 1 from the ChiNext board, and 1 from the Sci-Tech Innovation board [1] Group 3 - The average ratio of financing balance to circulating market value for stocks with large net purchases is 3.65%, with ZTE Communications having the highest ratio at 5.88% [2] - Other stocks with high financing balance ratios include Tonghua Golden Horse, Wo Ai Wo Jia, and Tuowei Information, with ratios of 5.33%, 5.32%, and 5.01%, respectively [2] - The financing net purchase rankings for April 18 show that Tuowei Information increased by 3.17%, while Hanwujing decreased by 1.10% [2]

Market Overview - The overall sentiment in the pharmaceutical sector remains optimistic, with the industry expected to see growth driven by macroeconomic factors and the recovery of public fund allocations to the sector [9][10]. - The CITIC Pharmaceutical Index decreased by 0.40%, underperforming the CSI 300 Index by 0.99 percentage points, ranking 22nd among 30 primary industries [5][6]. Stock Performance - The top-performing stocks this week included Shuangcheng Pharmaceutical, Lifang Pharmaceutical, and Shutaishen, with gains of 47.07%, 30.27%, and 28.77% respectively [4][5]. - Conversely, the worst performers were ST Jiyuan, Hasi Lian, and Jinhe Biological, with declines of 49%, 20%, and 10% respectively [4][5]. Investment Themes - The pharmaceutical sector is currently undervalued, with public funds showing low allocation to the industry. The anticipated recovery in macroeconomic conditions is expected to drive growth in the pharmaceutical sector by 2025 [9]. - In the innovative drug space, there is a shift from quantity to quality, emphasizing differentiated products and internationalization. Companies such as Hengrui, BeiGene, and Betta are recommended for investment [9][10]. - The medical device sector is witnessing a rebound in bidding volumes for imaging equipment, with companies like Mindray and United Imaging being highlighted for their growth potential [9][10]. White Album Market Outlook - China is highly dependent on imported albumin, with the market expected to reach approximately 235 billion yuan in 2024, reflecting an 8.4% decline year-on-year due to high base effects from 2023 and price reductions from centralized procurement [12][13]. - The domestic albumin market is characterized by a significant reliance on imports, with imported albumin accounting for 76% of the hospital market and 61% of the outpatient market [12][13]. Regulatory Changes and Tariffs - Recent tariff changes on U.S. imports, including a 125% tariff on imported albumin, may significantly impact the supply dynamics of the albumin market in China, potentially leading to a reduction in U.S. imports [15][20]. - The current pricing structure for imported albumin is under pressure, with limited ability to pass on tariff costs to end consumers, particularly in hospital settings [22][23]. Long-term Projections - The domestic albumin supply is expected to increase, with projections indicating that by 2024, domestic production could meet 40-41% of the market demand, creating opportunities for local manufacturers to capture market share from imports [29][30]. - The blood products industry is anticipated to experience a shift towards domestic alternatives, particularly in light of the current geopolitical climate and supply chain uncertainties [23][30].

Group 1 - The China Strategic Emerging Industries Index (New Emerging Index, 000171) closed up 0.14% at 1115.03 points, with a trading volume of 58.941 billion yuan [1] - Over the past month, the index has decreased by 11.00%, down 3.58% over the last three months, and down 5.99% year-to-date [1] - The index includes 100 representative listed companies from sectors such as energy conservation and environmental protection, new generation information technology, biotechnology, high-end equipment manufacturing, new energy, new materials, new energy vehicles, digital creativity, and high-tech services [1] Group 2 - The top ten weights in the index are: Dongfang Caifu (7.95%), BYD (6.47%), Hengrui Medicine (4.45%), Huichuan Technology (4.15%), Northern Huachuang (4.02%), Haiguang Information (3.41%), Luxshare Precision (3.05%), Mindray Medical (2.75%), Wanhua Chemical (2.47%), and Zhongji Xuchuang (2.37%) [1] - The market segments of the index holdings show that the Shenzhen Stock Exchange accounts for 59.48%, while the Shanghai Stock Exchange accounts for 40.52% [1] Group 3 - The industry composition of the index holdings includes: Information Technology (27.70%), Industrial (19.27%), Healthcare (14.92%), Communication Services (13.72%), Consumer Discretionary (9.66%), Financials (7.95%), Materials (6.13%), Utilities (0.34%), and Consumer Staples (0.31%) [2] - The index samples are adjusted semi-annually, with adjustments implemented on the next trading day after the second Friday of June and December each year [2] - Public funds tracking the New Emerging Index include: Huaxia Strategic Emerging Index ETF Connect A, Huaxia Strategic Emerging Index ETF Connect C, and Huaxia Strategic Emerging Index ETF [2]

Group 1 - The signing of a comprehensive cooperation agreement between Zhengzhou Airport and Shenzhen Mindray Biomedical Electronics marks a significant achievement in attracting investment in the biomedicine sector [3][9] - Mindray Medical is a global leader in medical devices, holding a crucial position in life information and support, in vitro diagnostics, and medical imaging [3][5] - Zhengzhou Airport aims to establish the Central Plains Medical Science City, focusing on integrating traditional Chinese and Western medicine, and has attracted numerous high-quality enterprises [5][9] Group 2 - The cooperation will involve creating an innovative medical engineering transformation platform, exploring the establishment of a national high-performance medical device sub-center, and planning a Mindray medical equipment storage center [5][9] - Mindray Medical expresses confidence in investing in Henan due to its strong industrial foundation, large market size, and promising development prospects [7][9] - The collaboration is expected to enhance regional medical service levels and technological innovation capabilities, benefiting both parties through mutual cooperation [9]

导读： 从中标金额来看，高分生物、贝克曼和睿钰分列前三，份额占比差距不大；从中标次数来看，瑞沃德、高分生物与睿钰稳居前三，赛默飞紧随其后。其余 进榜厂商如上海萌微、牛顿光学、博大博聚等竞争激烈。 特别提示 微信公众号机制调整，请点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 综合2 0 2 4全年各招标单位公布的中标信息，小编对2 0 2 4年细胞计数仪中标情况进行了全面盘点，整体上呈现出显著的集中化特征与差异化竞争 格局。 从中标金额来看，高分生物、贝克曼和睿钰分列前三，份额占比差距不大；从中标次数来看，瑞沃德、高分生物与睿钰稳居前三，赛默飞紧随 其 后 。 其 余 进 榜 厂 商 如 上 海 萌 微 、 牛 顿 光 学 、 博 大 博 聚 等 竞 争 激 烈 ， 但 整 体 市 场 仍 由 头 部 企 业 主 导 。 此 外 ， 包 括 Na n o e n t e k 、 艾 贝 泰 、 Bi o - Ra d等在内的多家国内外厂商亦参与竞逐，进一步丰富了市场供给的多样性。 从产品维度分析，中标数量TOP1 0型号中，瑞沃德C1 0 0 -SE、高分生物HD ...

Core Viewpoint - The recent announcement by the U.S. government to impose "reciprocal tariffs" on Chinese goods has prompted a swift response from several medical device companies, which have indicated they have comprehensive plans and measures in place to address the situation. Despite the complex impacts on the supply chain, the long-term trend towards self-sufficiency and international expansion in the medical device sector remains optimistic [1][2][7]. Company Responses - Multiple medical device companies have reported minimal impact from the U.S. tariff policy, citing pre-existing contingency plans. For instance, Mindray Medical has proactively stocked products in the U.S. ahead of previous tariff increases, ensuring that current sales are unaffected by the new tariffs [2][8]. - Kaili Medical stated that the U.S. market contributes only 1%-2% to its revenue, and prior inventory preparations have mitigated the tariff impact. The company has a well-established overseas market presence [3][8]. - Dirui Medical anticipates that its direct exports to the U.S. will be around $150,000 in 2024, representing a negligible portion of its overall revenue. The company has also identified measures to minimize the tariff's effects [3]. - Leshi Medical indicated that the tariff impact is manageable, as its U.S. operations focus on digital chronic disease management solutions, which have established long-term customer relationships [3][8]. - Weili Medical reported that its exports to the U.S. account for about 15% of total revenue, with a stable business model due to long-term partnerships and necessary certifications [4]. Industry Trends - The Chinese medical device industry is experiencing a push towards domestic production and innovation, particularly in high-end medical imaging and core components, where reliance on imports has been significant. Recent advancements in domestic R&D are enabling some companies to gain competitive advantages [4][6]. - The Ministry of Commerce has initiated anti-dumping investigations into imported medical CT tubes, which may benefit domestic suppliers and manufacturers [5]. - The Chinese government continues to support the medical device sector, promoting high-quality development and encouraging companies to expand internationally. This includes backing for high-end medical devices and innovative technologies [6][7]. - Analysts suggest that despite the tariff challenges, there is a strong potential for domestic companies to increase market share and reduce reliance on imports, particularly in high-value consumables and in vitro diagnostics (IVD) sectors [7]. Long-term Outlook - The long-term export potential for Chinese medical device companies remains positive, with a focus on expanding into developing markets outside the U.S. Companies like Mindray Medical are looking to enhance their brand presence in these regions [8]. - Companies are diversifying their international strategies, with plans for local production and sales in emerging markets such as Mexico, which is expected to commence operations by early 2026 [8].

Core Viewpoint - The China Securities Index for Healthcare Equipment and Services has shown a mixed performance, with a recent increase but a decline over the past month and year-to-date [1] Group 1: Index Performance - The CSI Healthcare Equipment and Services Index rose by 0.32% to 13,285.51 points, with a trading volume of 13.924 billion yuan [1] - Over the past month, the index has decreased by 8.06%, while it has increased by 4.05% over the last three months and has declined by 3.25% year-to-date [1] Group 2: Index Composition - The index is composed of listed companies in the healthcare sector, reflecting the overall performance of these securities [1] - The top ten weighted companies in the index include Mindray Medical (9.16%), Aier Eye Hospital (8.31%), and United Imaging Healthcare (7.43%) [1] - The index is primarily composed of companies listed on the Shenzhen Stock Exchange (60.27%) and the Shanghai Stock Exchange (39.73%) [1] Group 3: Sample Adjustment and Fund Tracking - The index samples are adjusted biannually, with adjustments occurring on the second Friday of June and December [2] - Public funds tracking the healthcare index include several funds from Southern Asset Management and Tianhong Asset Management [2]

Investment Rating - The report maintains a positive investment rating for the pharmaceutical industry, focusing on domestic substitution opportunities and quality overseas targets [3]. Core Insights - The report emphasizes the ongoing focus on domestic substitution opportunities in the pharmaceutical sector, including scientific instruments, medical devices, blood products, medical consumables, and pharmaceutical packaging. It also highlights the recovery of domestic pharmaceutical consumption driven by policies related to traditional Chinese medicine and medical services [1][2]. Summary by Sections 1. CXO - The CXO sector is expected to see valuation recovery due to supportive policies for innovative drug development and a decrease in geopolitical risks [7]. 2. Innovative Drugs - The report notes a decline in the A-share chemical preparation sector by 7% and a 3.74% drop in other biological products, indicating market volatility [10]. 3. Traditional Chinese Medicine - The report suggests focusing on companies like China Resources Sanjiu, Yunnan Baiyao, and Tongrentang, as the market anticipates further consumption stimulus policies [18]. 4. Blood Products - The report highlights the strong pricing power of scarce resource manufacturers and the growing demand for immunoglobulin, suggesting a positive outlook for companies like Tian Tan Biology and Shanghai RAAS [21]. 5. Vaccines - The vaccine sector is under pressure, but there is potential for growth in specific areas such as HPV vaccines and other high-value products [23]. 6. Upstream Supply Chain - The report recommends focusing on companies with strong brand effects and overseas growth potential in the chemical and biological reagent sectors [26]. 7. IVD - The report indicates that the IVD industry is undergoing significant changes due to procurement policies, which may accelerate domestic substitution and increase market penetration [29]. 8. Medical Devices - The report suggests that the CGM market is expected to grow, particularly with the FDA approval of new products, indicating a positive outlook for companies like Sanofi [34]. 9. Medical Services - The report recommends focusing on eye and dental service companies, as well as traditional Chinese medicine services, in light of new consumption policies [39]. 10. Pharmacies - The report indicates that the pharmacy sector is stabilizing, with a recommendation to focus on companies with strong supply chain capabilities [43]. 11. Raw Materials - The report notes that many raw material prices are stabilizing, suggesting potential investment opportunities in antibiotic intermediates and hormone raw materials [46]. 12. Innovative Instruments - The report emphasizes the potential for AI applications in the medical device sector, particularly in areas like surgical navigation and pathology screening [51]. 13. Low-value Consumables - The report highlights the potential for recovery in the low-value consumables sector, particularly for companies that can adapt to changing market conditions [60].